A common anesthesia drug could be beneficial in reducing pressure inside the skull of children with traumatic brain injuries (TBI), according to a new study.
Ketamine, a drug that has been used for anesthesia since the 1970s, has traditionally been avoided for patients with TBI due to early studies suggesting that it could raise the pressure inside of the skull, known as intracranial pressure (ICP).
And the results of this study have been hailed as having the potential to change more than 20 years of thinking on this topic, and helping to cast new light on the subject for the benefit of children with TBI going forward.
Lead author Dr Michael Wolf, assistant professor of pediatrics and neurological surgery and director of Neurocritical Care at Monroe Carell Jr. Children’s Hospital at Vanderbilt, and his co-authors set out to reexamine the effects of ketamine on ICP in children admitted to the paediatric intensive care unit (PICU) with severe TBI.
The study analysed data from 33 patients aged from one month to 16 years, 22 of whom received ketamine as part of a treatment protocol informed by evidence-based guidelines.
Eighteen ketamine doses were given during ICP crises in 11 patients, and an overall decrease in ICP was observed.
“We found that not only does ketamine not raise ICP, in some cases it may even lower it,” Dr Wolf said.
“Children with severe TBI are at risk of dying or having long-term neurologic impairment, such as difficulty walking and talking.
“In the crucial days following their initial injury, our focus in the PICU is to minimise ongoing damage to their brains, with a focus on preventing and treating high ICP.
“Despite decades of research, our treatment options remain limited to a handful of medicines and techniques.
“This study might help open the door to a new use of an old drug that could help us continue to improve our approach to caring for these vulnerable children.”
Dr Wolf said study the results are “exciting, though preliminary” because ketamine was associated with a reduction in ICP during ICP crises. If the findings are reproduced in a larger study, ketamine may warrant consideration as a treatment for intracranial hypertension in children with severe TBI, he said.
“Going forward, we plan to study the effects of ketamine in larger numbers of children with traumatic brain injury, partnering with colleagues at other children’s hospitals to do so,” Dr Wolf said.
“If we are able to improve our understanding of ketamine’s effects in a larger study, we might find that ketamine represents another tool to provide the best possible treatment for children with traumatic brain injury.”
The study results could reverse nearly two decades of thinking related to ketamine and intracranial pressure, according to co-author Dr John C. “Jay” Wellons, III, Cal Turner Chair and chief of Pediatric Neurosurgery at Monroe Carell.
“This is a terrific example of what the paediatric neurocritical care effort is capable of,” Wellons said.
“Dr. Wolf and his paediatric ICU colleagues not only provide excellent care, but also conduct field-impacting clinical research.
“This study alone represents a near complete reversal in how we think about the relationship between ketamine and intracranial pressure.
“The results will likely lead to further studies that I believe will change 20 years of past thinking.”
